Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Key Metrics
MCK logo

McKesson Surges 18% in Q3 Revenues Amid Specialty Drug Boom

MCK10-QFiling Date: 2/6/2025
McKesson Corporation
Description

What this story covers

McKesson reported Q3 revenues of $95.3 billion, up 18%, driven by U.S. pharmaceutical and specialty growth. Operating income doubled to $1.2 billion, EPS rose 57% to $6.95. Segments show strength despite restructuring and opioid liabilities; strategic divestitures and acquisitions enhance focus on core services. Liquidity solid via credit facilities; $3.1 billion returned to shareholders. No new risk changes.

Story snapshot

CompanyMcKesson Corporation
TickerMCK
VariantStandard detailed
Duration13:33
Filing type10-Q
PeriodQ4 2024
IndustryHealthcare & Pharmaceuticals
Accession0000927653-25-000014

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in